CYP2D6 phenotypes and Parkinson's disease risk: A meta-analysis

Journal of the Neurological Sciences

Volumn 336, Issue 1-2, 2014, Pages 161-168

  Lu, Yu ^a   Peng, Qiliu ^a   Zeng, Zhiyu ^a   Wang, Jian ^a   Deng, Yan ^a   Xie, Li ^a   Mo, Cuiju ^a   Zeng, Jie ^b   Qin, Xue ^a   Li, Shan ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b LIUZHOU PEOPLE S HOSPITAL   (China)

Author keywords

CYP2D6; Meta analysis; Metabolizer; Parkinson's disease; Phenotypes; Polymorphisms

Indexed keywords

CYTOCHROME P450 2D6;

ARTICLE; CAUCASIAN; COMPARATIVE STUDY; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; META ANALYSIS; ONSET AGE; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

CYP2D6; META-ANALYSIS; METABOLIZER; PARKINSON'S DISEASE; PHENOTYPES; POLYMORPHISMS;

CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; HUMANS; OBSERVATIONAL STUDY AS TOPIC; PARKINSON DISEASE; PHENOTYPE; RISK FACTORS;

EID: 84892601053     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2013.10.030     Document Type: Article

References (55)

1. W G The pathology of parkinsonian disorders N. Quinn, P. Jenner, Disorders of movement London 1989 Academic Press 33 57
2. M.C. de Rijk et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study European Community Concerted Action on the Epidemiology of Parkinson's disease J Neurol Neurosurg Psychiatry 62 1 Jan 1997 10 15
3. M.T. Landi, M. Ceroni, E. Martignoni, P.A. Bertazzi, N.E. Caporaso, and G. Nappi Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism Adv Neurol 69 1996 61 72
4. C.M. Tanner Epidemiology of Parkinson's disease Neurol Clin 10 2 May 1992 317 329
5. R.L. Nussbaum, and M.H. Polymeropoulos Genetics of Parkinson's disease Hum Mol Genet 6 10 1997 1687 1691
6. O. Bandmann, J. Vaughan, P. Holmans, C.D. Marsden, and N.W. Wood Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease Lancet 350 9085 Oct 18 1997 1136 1139
7. C.A. Smith et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease Lancet 339 8806 Jun 6 1992 1375 1377
8. M. Armstrong, A.K. Daly, S. Cholerton, D.N. Bateman, and J.R. Idle Mutant debrisoquine hydroxylation genes in Parkinson's disease Lancet 339 8800 Apr 25 1992 1017 1018
9. M.J. Steiger, P. Lledo, N.P. Quinn, C.D. Marsden, P. Turner, and P.G. Jenner Debrisoquine hydroxylation in Parkinson's disease Acta Neurol Scand 86 2 Aug 1992 159 164
10. M.C. Kurth, and J.H. Kurth Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease Am J Med Genet 48 3 Oct 15 1993 166 168
11. V. Plante-Bordeneuve, M.B. Davis, D.M. Maraganore, C.D. Marsden, and A.E. Harding Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease J Neurol Neurosurg Psychiatry 57 8 Aug 1994 911 913
12. J.A. Agundez et al. Association between the oxidative polymorphism and early onset of Parkinson's disease Clin Pharmacol Ther 57 3 Mar 1995 291 298
13. R. Bordet, F. Broly, A. Destee, C. Libersa, and J.J. Lafitte Lack of relation between genetic polymorphism of cytochrome P-450IID6 and sporadic idiopathic Parkinson's disease Clin Neuropharmacol 19 3 Jun 1996 213 221
14. M.S. Sandy et al. CYP2D6 allelic frequencies in young-onset Parkinson's disease Neurology 47 1 Jul 1996 225 230
15. N. Diederich et al. Genetic variability of the CYP 2D6 gene is not a risk factor for sporadic Parkinson's disease Ann Neurol 40 3 Sep 1996 463 465
16. G. Lucotte, J.C. Turpin, N. Gerard, S. Panserat, and R. Krishnamoorthy Mutation frequencies of the cytochrome CYP2D6 gene in Parkinson disease patients and in families Am J Med Genet 67 4 Jul 26 1996 361 365
17. T. Gasser et al. The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease J Neurol Neurosurg Psychiatry 61 5 Nov 1996 518 520
18. S.J. McCann, S.M. Pond, K.M. James, and D.G. Le Couteur The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis J Neurol Sci 153 1 Dec 9 1997 50 53
19. K. Wilhelmsen et al. Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q13? Ann Neurol 41 6 Jun 1997 813 817
20. M.A. Bon, E.N. Jansen Steur, R.A. de Vos, and I. Vermes Neurogenetic correlates of Parkinson's disease: apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism Neurosci Lett 266 2 May 7 1999 149 151
21. N. Sabbagh et al. CYP2D6 polymorphism and Parkinson's disease susceptibility Mov Disord 14 2 Mar 1999 230 236
22. A. Atkinson et al. CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy Bodies or Alzheimer's disease Pharmacogenetics 9 1 Feb 1999 31 35
23. O. Joost et al. Absence of effect of seven functional mutations in the CYP2D6 gene in Parkinson's disease Mov Disord 14 4 Jul 1999 590 595
24. D.J. Nicholl et al. A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism Neurology 53 7 Oct 22 1999 1415 1421
25. M. Stefanovic, E. Topic, A.M. Ivanisevic, M. Relja, and M. Korsic Genotyping of CYP2D6 in Parkinson's disease Clin Chem Lab Med 38 9 Sep 2000 929 934
26. D.M. Maraganore, M.J. Farrer, J.A. Hardy, S.K. McDonnell, D.J. Schaid, and W.A. Rocca Case-control study of debrisoquine 4-hydroxylase, N-acetyltransferase 2, and apolipoprotein E gene polymorphisms in Parkinson's disease Mov Disord 15 4 Jul 2000 714 719
27. B.S. Harhangi, B.A. Oostra, P. Heutink, C.M. van Duijn, A. Hofman, and M.M. Breteler CYP2D6 polymorphism in Parkinson's disease: the Rotterdam Study Mov Disord 16 2 Mar 2001 290 293
28. H. Payami et al. Parkinson's disease, CYP2D6 polymorphism, and age Neurology 56 10 May 22 2001 1363 1370
29. M. Bialecka et al. Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson's disease Parkinsonism Relat Disord 13 4 May 2007 224 229
30. G. Duric, M. Svetel, S.I. Nikolaevic, N. Dragadevic, J. Gavrilovic, and V.S. Kostic Polymorphisms in the genes of cytochrome oxidase P450 2D6 (CYP2D6), paraoxonase 1 (PON1) and apolipoprotein E (APOE) as risk factors for Parkinson's disease Vojnosanit Pregl 64 1 Jan 2007 25 30
31. M. Golab-Janowska, K. Honczarenko, B. Gawronska-Szklarz, and A. Potemkowski CYP2D6 gene polymorphism as a probable risk factor for Alzheimer's disease and Parkinson's disease with dementia Neurol Neurochir Pol 41 2 Mar-Apr 2007 113 121
32. R. Vilar et al. Association of A313 G polymorphism (GSTP1*B) in the glutathione-S-transferase P1 gene with sporadic Parkinson's disease Eur J Neurol 14 2 Feb 2007 156 161
33. J. Halling, M.S. Petersen, P. Grandjean, P. Weihe, and K. Brosen Genetic predisposition to Parkinson's disease: CYP2D6 and HFE in the Faroe Islands Pharmacogenet Genomics 18 3 Mar 2008 209 212
34. A. Mann, S.L. Miksys, A. Gaedigk, S.J. Kish, D.C. Mash, and R.F. Tyndale The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients Neurobiol Aging 33 9 Sep 2012 2160 2171
35. C. Sachse, J. Brockmoller, S. Bauer, and I. Roots Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences Am J Hum Genet 60 2 Feb 1997 284 295
36. A. Gaedigk, S.D. Simon, R.E. Pearce, L.D. Bradford, M.J. Kennedy, and J.S. Leeder The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype Clin Pharmacol Ther 83 2 Feb 2008 234 242
37. Z. Zeng et al. CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis Cancer Chemother Pharmacol 72 2 Aug 2013 287 303
38. D.E. Gilham et al. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization Xenobiotica 27 1 Jan 1997 111 125
39. T. Hiroi, S. Imaoka, and Y. Funae Dopamine formation from tyramine by CYP2D6 Biochem Biophys Res Commun 249 3 Aug 28 1998 838 843
40. Y. Deng, B. Newman, M.P. Dunne, P.A. Silburn, and G.D. Mellick Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease Ann Neurol 55 6 Jun 2004 897
41. A. Elbaz et al. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease Ann Neurol 55 3 Mar 2004 430 434
42. J. Ferlay SH et al. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 2008 International Agency for Research on Cancer Year [M] Lyon, France
43. S. Zareparsi, T.D. Taylor, E.L. Harris, and H. Payami Segregation analysis of Parkinson disease Am J Med Genet 80 4 Dec 4 1998 410 417
44. Y.C. Lou, L. Ying, L. Bertilsson, and F. Sjoqvist Low frequency of slow debrisoquine hydroxylation in a native Chinese population Lancet 2 8563 Oct 10 1987 852 853
45. E. Steiner, L. Bertilsson, J. Sawe, I. Bertling, and F. Sjoqvist Polymorphic debrisoquin hydroxylation in 757 Swedish subjects Clin Pharmacol Ther 44 4 Oct 1988 431 435
46. D.F. Stroup et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group JAMA 283 15 Apr 19 2000 2008 2012
47. A. Thakkinstian, P. McElduff, C. D'Este, D. Duffy, and J. Attia A method for meta-analysis of molecular association studies Stat Med 24 9 May 15 2005 1291 1306
48. R. Fonne-Pfister, M.J. Bargetzi, and U.A. Meyer MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation Biochem Biophys Res Commun 148 3 Nov 13 1987 1144 1150
49. H.B. Niznik et al. The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins Arch Biochem Biophys 276 2 Feb 1 1990 424 432
50. B. Wang, L.P. Yang, X.Z. Zhang, S.Q. Huang, M. Bartlam, and S.F. Zhou New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme Drug Metab Rev 41 4 2009 573 643
51. A. Mann, and R.F. Tyndale Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells Eur J Neurosci 31 7 Apr 2010 1185 1193
52. N. Bozina, V. Bradamante, and M. Lovric Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk Arh Hig Rada Toksikol 60 2 Jun 2009 217 242
53. N. Wood Genes and parkinsonism J Neurol Neurosurg Psychiatry 62 4 Apr 1997 305 309
54. J.A. Agundez, C. Martinez, M.C. Ledesma, M.G. Ladona, J.M. Ladero, and J. Benitez Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations Clin Pharmacol Ther 55 4 Apr 1994 412 417
55. A. Rostami-Hodjegan, M.S. Lennard, H.F. Woods, and G.T. Tucker Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease Pharmacogenetics 8 3 Jun 1998 227 238